Hospital News and Research

RSS

Growing public health threat from surge in drug-resistant strains of acinetobacter

A new study in the journal Infection Control and Hospital Epidemiology reports a surge in drug-resistant strains of Acinetobacter, a dangerous type of bacteria that is becoming increasingly common in U.S. hospitals. This study is being posted online today and will appear in the journal's February print edition.

24 Dec 2009

Study reveals genomic switches separate autoimmune disorders in different clusters

Genomic switches can predispose an individual to one set of autoimmune disorders but protect the same person against another set of them, scientists at Stanford University School of Medicine have found.

24 Dec 2009

LUHS urogynecologists awarded $1M NIH Challenge Grant

The National Institutes of Health (NIH) has awarded a Challenge Grant for $1 million to Loyola University Health System (LUHS) urogynecologists Kimberly Kenton, MD, and Elizabeth Mueller, MD. This places them among the top 2 percent of researchers in the nation to receive this grant.

24 Dec 2009

National Council on Aging favors Senate health reform bill

The National Council on Aging supports the Senate for its Patient Protection and Affordable Care Act (H.R. 3590), which, when passed, will bring America one giant step closer to the long-awaited goal of health care that is both accessible and affordable for Americans of all ages.

24 Dec 2009

Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor

Forest Laboratories announced today its agreement to acquire additional rights to NXL 104, which amends the terms of its prior agreement with Novexel covering the combination of NXL 104 with ceftaroline and adds additional rights to the combination of ceftazidime and NXL 104, through a transaction with AstraZeneca executed immediately following AstraZeneca’s announced acquisition of Novexel, S.A.

24 Dec 2009

Fitch Ratings affirms OMHS' Kentucky $502M revenue bonds 'BBB+'

Fitch Ratings assigns a 'BBB+' rating to the following City of Owensboro, Kentucky health system revenue bonds: -- $502.3 million series 2010 City of Owensboro, Kentucky health system revenue bonds (Owensboro Medical Health System).

24 Dec 2009

New compound may halt drug-resistant lung cancer

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.

24 Dec 2009

Fitch Ratings affirms Siskin's TN variable-rate demand bonds at 'A-'

Fitch Ratings takes the following rating action on Siskin Hospital for Physical Rehabilitation, Inc. (Siskin) as part of its continuous surveillance effort: -- approximately $5.8 million Chattanooga Health, Educational, and Housing Facility Board, TN variable-rate demand bonds, series 1990A, affirmed at 'A-'.

24 Dec 2009

Angelica partners with HSC to provide quality healthcare for Haitian community

At Angelica, we are committed to meeting the highest standards of corporate citizenship by fulfilling our mission to offer healthcare providers superior services based on our high quality products, unsurpassed quality and service standards, and creative solutions. While we strive to achieve that mission in the communities where we do business, we embrace opportunities where we can support communities outside our geographical footprint through charitable activities.

24 Dec 2009

AstraZeneca signs definitive agreement to acquire Novexel

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial drug resistance, announces today that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company at closing.

24 Dec 2009

Pyng Medical releases audited fiscal 2009 results for September 30, 2009

Pyng Medical Corp. today released its audited fiscal 2009 results for the year ended September 30, 2009. Pyng reported fourth quarter sales were $1,718,272 and total annual sales of $6,026,177. Net loss before tax for the year was $62,904 and after tax was $246,904.

24 Dec 2009

LA hospital illustrates dilemma of expensive end of life care

End-of-life care has become a target for critics who allege many hospitals and physicians order unnecessary and expensive procedures, but it often involves difficult and complex decision-making. The New York Times reports on one hospital with large end-of-life care bills:

24 Dec 2009

Lawmakers brace for conference as House Liberals vow not to give in on key issues

The Los Angeles Times reports that Democrats are looking ahead — and at each other — before beginning the "potentially difficult" process of reconciling the Senate and House versions of health care reform.

23 Dec 2009

Nursing shortage awaits baby boomers

CNNMoney reports: "Baby boomers are getting older and will require more care than ever, taxing an already strained nursing system. America has had a nursing shortage for years, said Peter Buerhaus, workforce analyst at Vanderbilt University School of Nursing in Nashville, Tenn. But by 2025, the country will be facing a shortfall of 260,000 RNs, he said."

23 Dec 2009

Discovery enables scientists to devise novel strategies to diagnose and treat brain cancer

A team of Columbia scientists have discovered two genes that, when simultaneously activated, are responsible for the most aggressive forms of human brain cancer.

23 Dec 2009

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure.

23 Dec 2009

Hospital News and Research

Growing public health threat from surge in drug-resistant strains of acinetobacter

Study reveals genomic switches separate autoimmune disorders in different clusters

LUHS urogynecologists awarded $1M NIH Challenge Grant

National Council on Aging favors Senate health reform bill

Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor

Fitch Ratings affirms OMHS' Kentucky $502M revenue bonds 'BBB+'

New compound may halt drug-resistant lung cancer

Fitch Ratings affirms Siskin's TN variable-rate demand bonds at 'A-'

Angelica partners with HSC to provide quality healthcare for Haitian community

AstraZeneca signs definitive agreement to acquire Novexel

Pyng Medical releases audited fiscal 2009 results for September 30, 2009

LA hospital illustrates dilemma of expensive end of life care

Lawmakers brace for conference as House Liberals vow not to give in on key issues

Nursing shortage awaits baby boomers

Discovery enables scientists to devise novel strategies to diagnose and treat brain cancer

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Industries brace for health overhaul as Senate nears deal

Majority of Australians think H1N1 vaccination is not necessary

Motility mechanism of malaria pathogens explained

GlobalPost examines antibiotic resistance in China

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News